Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Iproheptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iproheptine SCHEMBL23902081 | 0.97 | LMNA (0.46) | LMNATDP1MEN1ALDH1A1HTT | |
| Iproheptine SCHEMBL48719 | 0.97 | LMNA (0.46) | LMNATDP1MEN1ALDH1A1HTT | |
| Iproheptine SCHEMBL18541892 | 0.97 | LMNA (0.46) | LMNATDP1MEN1ALDH1A1HTT | |
| SCHEMBL277041 | 0.86 | LMNA (0.50) | LMNAMEN1ALDH1A1HTTKMT2A | |
| SCHEMBL19080590 | 0.80 | TDP1 (0.41) | LMNATDP1ALDH1A1APEX1PMP22 | |
| Hydrochloric Acid SCHEMBL11540172 | 0.77 | TDP1 (0.33) | TDP1APEX1PMP22 | |
| SCHEMBL17198262 | 0.77 | LMNA (0.42) | LMNAMEN1ALDH1A1HTTKMT2A | |
| SCHEMBL20210214 | 0.76 | TDP1 (0.50) | TDP1APEX1PMP22CYP1A2CYP2D6 | |
| SCHEMBL12201612 | 0.76 | ADH1B (0.41) | TDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL21118983 | 0.76 | LMNA (0.46) | LMNAMEN1ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-4748383-A1 | OPHTHALMIC COMPOSITION | Rohto Pharmaceutical Co., Ltd. (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20250228887-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-17 | — | — | US | disclosed |
| WO-2025053216-A1 | OPHTHALMIC COMPOSITION | ロート製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025053197-A1 | OPHTHALMIC COMPOSITION | ロート製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024262353-A1 | COMPOSITION FOR ORAL CAVITY | ライオン株式会社 | 2024-12-26 | — | — | WO | disclosed |
| US-20240390416-A1 | OPHTHALMOLOGICAL COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-4393510-A1 | OPHTHALMOLOGICAL COMPOSITION | Rohto Pharmaceutical Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393496-A1 | OPHTHALMIC COMPOSITION | Rohto Pharmaceutical Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-12005070-B2 | Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder | TOYO SUGAR REFINING CO., LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| EP-0968712-A1 | FELBINAC-CONTAINING PATCH | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2000-01-05 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-5428056-A | Terpene amino alcohols and medicinal uses thereof | KURARAY CO., LTD. (JP) | 1995-06-27 | — | — | US | disclosed |
| US-5284850-A | Antiallergens, improve cerebral function | KURARAY CO., LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0209158-B1 | Terpene amino alcohols and medicinal uses thereof | KURARAY CO (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5143921-A | Antiallergens, improving cerebral function | KURARAY CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| US-4946857-A | ANTIALLERGENS; IMPROVE CEREBRAL FUNCTION | KURARAY CO., LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| EP-0209158-A2 | Terpene amino alcohols and medicinal uses thereof | KURARAY CO., LTD. (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12005070-B2 | Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder | UGCG, GBA1, GOLGA2 | LMNA 1761/4885TDP1 3494/4885MEN1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.